1. Biotech IPO bonanza: Legend Biotech, Forma Therapeutics, Repare — COVID-19 could slow progress in reducing cancer death, NCI warns — ASCO 2020 news from Merck, AstraZeneca, Pfizer, more — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Is Shionogi looking at Achaogen

Discussion in 'Shionogi' started by anonymous, May 12, 2019 at 4:22 PM.

  1. anonymous

    anonymous Guest

    To buy it’s Zemdri- Plazomicin. FDA approved and from the looks EMA is a shoe in and will go toe to toe with Astra
     

  2. anonymous

    anonymous Guest

    At what price ??
     
  3. anonymous

    anonymous Guest

    Lol shares obviously
     
  4. anonymous

    anonymous Guest

    scale-ability- capex and resources is what Achaogen failed at.
     
  5. anonymous

    anonymous Guest

    Me thinks so
     
  6. anonymous

    anonymous Guest

    Achaogen can’t take all the blame. The blame should be put on the PharmDs and IDs that shelve all new abxs and cause reps to lose their jobs and companies to fold. Ultimate culpability lies with the government and their unwillingness to change the reimbursement model.
     
  7. anonymous

    anonymous Guest

    shionogi should buy Allergan’s antibiotic line